WeiQi Lin, M.D., Ph.D.

WeiQi Lin, M.D., Ph.D., joined DURECT in 2008 and is currently Executive Vice President of Research and Development, Principal Scientist. Dr. Lin has been instrumental in DURECT’s epigenetic regulator program, identifying the opportunities presented by larsucosterol and guiding the program since DURECT in-licensed worldwide rights from Virginia Commonwealth University (VCU) to the Phase 2 clinical development stage. She has more than 26 years of industry experience after starting her career at ALZA Corporation, then moving on to Johnson and Johnson and Encinal Pharmaceuticals, prior to joining DURECT with increased responsibilities. Dr. Lin received her medical degree from Shanghai Medical University, her doctorate in pharmacology/toxicology from Virginia Commonwealth University, and postdoctoral training from Stanford University and the University of California at San Francisco.